{"doi":"10.4314/jpb.v22i1.4","title":"Role of peroxisome proliferator-activated receptor (PPARα) in mediating renoprotective effects of fumarate","abstract":"Fumarate has been reported to exert renoprotective actions. This study investigated a potential association between renoprotective activities of fumarate and peroxisome proliferator activated receptor (PPARα). PPARα wild type (WT) and knockout (KO) mice were randomly grouped into three groups; control (mineral oil + distilled water, 10 mL/kg/day, p.o.), fumarate (1 mg/kg/day, p.o.) and fenofibrate (100 mg/kg/day, p.o.). Mice were treated for 10 days, after which they were anaesthetized with xylazine + ketamine, 100 mg/kg i.p. Cortical blood flow (CBF) was then measured using a laser Doppler. Biochemical analyses were carried out. Fumarate reduced CBF in PPARα WT mice compared to PPAR KO mice (280.3 ± 34.2 vs 449.8 ± 15 PU, p<0.05). Nitric oxide production was significantly lower in fumarate-treated PPAR WT compared to PPAR KO mice (13.6 ± 1 vs 20.9 ± 3 μM/ng, p<0.05). Catalase activitywas insignificantly different in PPAR WT and KO mice treated with fumarate (p>0.05. Superoxide dismutase (SOD) activity was reduced by two-fold in PPAR WT mice compared to PPAR KO mice (p<0.05). This study demonstrates that the effect of fumarate on CBF, nitric oxide and L-arginine metabolism may be partially modulated through the PPARα downstream signalling pathway.","journal":"Journal of Pharmacy & Bioresources","year":2025,"id":533214,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9639,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":967623,"name":"Myung Gil Choi","orcid":"0000-0002-3128-2202","position":1,"is_corresponding":false},{"id":457170,"name":"Ighodaro Igbe","orcid":"0000-0003-0032-119X","position":2,"is_corresponding":false},{"id":946162,"name":"Adebayo Oyekan","orcid":"0000-0002-8966-3921","position":3,"is_corresponding":false},{"id":946161,"name":"Osaze Edosuyi","orcid":"0000-0001-8566-3265","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:51:32.301795Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}